ClinicalTrials.gg
TerminatedNCT00731692INFORMSUpdated Jun 14, 2017Results posted

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

A Phase 3 interventional study of FTY720 and Placebo in Primary Progressive Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Terminated at 157 sites in 18 countries. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
The extension study was terminated early after the results of the core study showed the study did not meet primary endpoint; confirmed disability progression

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
970
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis — 1 open to participants now, 2 under way, 1 of them phase 3. Multiple Sclerosis, Chronic Progressive · Novartis.

Started
2008
the only one that year
Phase 3
3 of 16
1 open now
Registered
1st of 16
by date

Among the 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis, this one is the only one that started in 2008, is one of 3 in phase 3, and was the 1st registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

1 of the 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS. This was an open-label, single-arm extension study to a double-blind, randomized multicenter, placebo-controlled, parallel-group core study. The core study completed and eligible patients enrolled into the extension study at the next scheduled or unscheduled core study visit. All patients, regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension study. The extension study was terminated early after the results of the core study became available showing that the study did not meet its primary endpoint which was defined as confirmed disability progression in this population

03

Conditions studied

  • Primary Progressive Multiple Sclerosis

Keywords

  • FTY720, primary progressive multiple sclerosis,PPMS
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General

  1. sign written prior to participating in the study
  2. 25 through 65 years of age inclusive
  3. females of must:

    • have a negative pregnancy test at Baseline (prior to randomization) and
    • use simultaneously two forms of effective during the treatment and 3-months after discontinuation of study medication

Primary Progressive Multiple sclerosis.

  1. diagnosis of primary progressive multiple sclerosis (according to the 2005 Revised McDonald criteria):
  2. time since first reported symptoms between 2 and 10 years
  3. evidence of clinical disability progression in the 2 years prior to Screening
  4. disability status at Screening

    • EDSS score of 3.5-6.0 inclusive
    • pyramidal functional system score of 2 or more
    • 25'TWT less than 30 seconds

Extension study Inclusion criteria

  • Patients initially randomized to fingolimod 1.25 mg or placebo as part of the first study cohort, were to have completed at least 3 years on study drug treatment at the time of extension study initiation.
  • Patients initially randomized to fingolimod 0.5 mg or placebo as part of the second study cohort, were to have continued on study drug treatment until such time as the last ongoing patient enrolled in the study had reached 3 years in study

Exclusion criteria

Exclusion Criteria:

PPMS specific:

  • History of relapses/attacks
  • Progressive neurological disorder other than PPMS
  • Pure cerebellar syndrome or pure visual progressive syndrome or pure
  • cognitive progressive syndrome
  • Presence of spinal cord compression at screening MRI
  • Relevant history of vitamin B12 deficit
  • Evidence of syphilis or borreliosis at Screening

Cardiovascular conditions:

  • Myocardial infarction within the past 6 months or current unstable ischemic heart disease
  • History of angina pectoris due to coronary spasm or history of Raynaud's phenomenon
  • Severe cardiac failure or cardiac arrest
  • History of symptomatic bradycardia
  • Resting pulse \<55 bpm pre-dose
  • History of sick sinus syndrome or sino-atrial heart block
  • History or presence of second and third degree AV block or an increase (QTc>440 ms)
  • Arrythmia requiring treatment with class III antiarrythmic drugs
  • History of positive tilt test from workout of vasovagal syncope
  • Hypertension, not controlled with medication

Pulmonary:

  • Severe respiratory disease or pulmonary fibrosis
  • TB
  • Abnormal X-ray, suggestive of active pulmonary disease
  • Abnormal PFT: \<70% of predicted for and FVC; \<60% for DLCO
  • Patients receiving chronic (daily) therapies for asthma

Hepatic:

  • Known history of alcohol abuse, chronic liver or biliary disease
  • Total or conjugated Brb >, unless in context of Gilbert's syndrome
  • AP >1.5xULN; /AST >2xULN; GGT>3xULN

Other:

  • History of chronic disease of the immune system other than MS
  • (other than successfully treated SCC or BCC)
  • Diabetes Mellitus
  • Macular Edema present at screening
  • , or B, other active infection
  • History of total lymphoid irradiation or bone marrow transplantation
  • Serum creatinine >1.7 mg/dl
  • WBC \<3500 cells/mm3
  • Lymphocyte count \<800 cells/mm3
  • History of substance abuse or any other factor that may interfere with subject ability to cooperate and comply with the study procedures
  • Unable to undergo MRI scans
  • Participation in any therapeutical clinical research study in the 6 months prior to randomization
  • Pregnant or lactating women
  • Drugs requiring :

    3 months:

    • Systemic or ACTH
    • INF-beta

      6 months:

    • medication
    • Immunoglobulins
    • Monoclonal antibodies
  • Drugs that exclude participation in the study:
  • Cladribine
  • Cyclophosphamide
  • Mitoxantrone (except: patients who received a cumulative dose of no more than 60mg/m2 more than 5 years ago could enter the study)

Extension study Exclusion criteria

-Patients were not eligible for enrollment in the extension study if they had any of the following key exclusion criteria at the extension study Baseline visit: active chronic immune system disease other than MS (or stable disease treated with immune therapy); known immunodeficiency syndrome; active infection; uncontrolled diabetes mellitus; macularedema; treatment with Class Ia or III antiarrhythmic drugs; any of the specified cardiac, pulmonary, or hepatic conditions; or any medically unstable condition

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
970 participants (actual)

Study arms

  • Experimental
    FTY720D 0.5 mg

    Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment

    Drug: FTY720

  • Placebo comparator
    Placebo

    Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization

    Drug: Placebo

  • Experimental
    FTY720D 1.25 mg switch to 0.5 mg

    Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009

    Drug: FTY720

Interventions

  • DrugFTY720

    Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily

  • DrugPlacebo

    Matching placebo capsules were administered orally once daily

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint

    3-month sustained increase from Baseline in EDSS (at least 1 point increase from Baseline for patients with a Baseline value of 5 or less or at least 0.5 point increase from Baseline for patients with a Baseline value of 5.5 or more) or 3-month sustained increase of at least 20% from BL in the time taken to complete the timed 25-foot walk test (25' TWT); or 3-month sustained increase of at least 20% from BL in the time taken to complete the 9-HPT. The 25' TWT is a quantitative measure of lower extremity function. The EDSS is a scale assessing neurologic impairment, including a series of scores in each of 8 functional systems: Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. The score ranges from 0 (normal) to 10 (death due to MS)). The 9-hole peg test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function.

    Time frame: up to 36 months after the last patient was randomized

Secondary outcomes

  1. Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)

    The Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in MS (Kurtzke 1983) and includes a series of scores in each of 8 functional systems and the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Fatigue is not included in the Cerebral score of the EDSS. The score ranges from 0 (normal) to 10 (death due to MS)

    Time frame: up to 36 months after the last patient was randomized

  2. Percent Change From Baseline in Brain Volume at Month 36

    The percent change from Baseline in brain volume was analyzed using a random coefficients model. The model included: 1) fixed effects: treatment and region and 2) continuous covariates: time, number of Gd enhancing lesions at Baseline, Baseline T2 volume, and normalized brain volume at Baseline. Time as a continuous covariate allowed for the estimation of different slopes and intercepts among treatment groups.

    Time frame: Baseline to month 36

  3. Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT.

    The 9-HPT is a quantitative measure of upper extremity (arm and hand) function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis

    Time frame: up to 36 months after the last patient was randomized

  4. Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT.

    The 25' TWT is a quantitative measure of lower extremity function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis

    Time frame: up to 36 months after the last patient was randomized

  5. Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36

    Inflammatory disease, as measured by number of new or newly-enlarging T2 lesions, was assessed by Magnetic resonance Imaging (MRI) scanning of the brain and full spinal cord. N= Total number of patients included in the analysis

    Time frame: Baseline to 36 months

  6. Number of Gd-enhancing Lesions at Month 36

    Inflammatory disease, as measured by number of T1 Gd-enhancing lesions, was assessed by MRI scanning of the brain and full spinal cord. N= Total number of patients included in the analysis

    Time frame: Baseline to 36 months

  7. Percent Change in Total T2 Lesion Volume From Baseline to Month 36

    Inflammatory disease as measured by percent change in total T2 lesion volume (mm3) was assessed by MRI. N= Total number of patients included in the analysis

    Time frame: Baseline to month 36

  8. Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score)

    The quality of life scale contains 22 items. Each item will be given a score of 1 or 0. A score of 1 (or 0) indicates the presence (or absence) of the symptom or adverse quality of life. All 22 item scores will be summed to obtain a total score ranging from 0 (good) to 22 (poor), which is the PRIMUS QoL scale score

    Time frame: Baseline, 36 months

  9. Change From Baseline in PRIMUS-Activities

    The activities subscale of PRIMUS contains 15 items and each item is given a score of 0 (able to do on own without difficulties), 1 (able to do on own with difficulties), or 2 (unable to do on own). All 15 items were summed to obtain a total score ranging from 0 (good) to 30 (poor).

    Time frame: Baseline, 36 months

  10. Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score

    Unidimensional Fatigue Impact Scale (U-FIS), contains 22 patient-reported items that assess the impact of fatigue on cognitive, physical, and psychosocial functioning. Responses formed a single unidimensional scale measuring fatigue impact. The U-FIS was calculated and analyzed according to the U-FIS scoring manual. The U-FIS scale contains 22 items with 5 possible outcomes for each item. Two response categories (about half the time and a lot of the time) were combined into 1 category to obtain 4 possible outcomes: 0 (never), 1 (a little of the time), 2 (about half the time/a lot of the time), and 3 (all the time). The 22 condensed item scores were summed to obtain a total score ranging from 0 (no fatigue) to 66 (severe fatigue impact).

    Time frame: Baseline, 36 months

  11. Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D Score)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Baseline, 36 months

  12. Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score)

    The Multiple Sclerosis Walking Scaleis a patient reported measure of walking quality (Hobart et al 2003), consisting of 12 items asking patients to rate the impact of MS upon their walking ability. Responses were captured on a 3-point scale ranging from 1 (Not at all) to 3 (A lot) for items 1 to 3 and on a 5-point scale ranging from 1 (not limited) to 5 (extremely) for items 4 to 12. All 12 item scores were summed to obtain a total score ranging from 12 (good) to 54 (poor) which is the MSWS-12 scale score. The total score was transformed to a 0 to 100 scale score. The MSWS-12 scale score will be transformed to a 0-100 scale score before any summaries or statistical analyses are performed. The transformed score is obtained by subtracting 12 and divided by 42 and multiplying by 100 (i.e., transformed scale score = (raw scale score- 12)/42\*100).

    Time frame: Baseline, 36 months

  13. Blood Concentrations of Fingolimod and Fingolimod-phosphate

    Concentrations of fingolimod and fingolimod-phosphate in whole blood were determined by validated liquid chromatography methods with tandem mass spectrometry. The lower limits of quantification were 0.08 ng/ml for fingolimod and 0.1 ng/ml for fingolimod-phosphate. Venous blood samples were collected for the analysis.

    Time frame: Month 3 up to 36 months

  14. Change in MSFC Z-score and Subscale Scores From Baseline to Month 36

    The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The overall MSFC z-score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population. Higher scores reflect better neurological function and a positive change from Baseline indicates improvement.

    Time frame: Baseline to Month 36

07

Results

Posted Jun 14, 2017

Participant flow

Patients were randomized equally to receive either fingolimod or placebo. Patients initially randomized to fingolimod 1.25 mg/day or matching placebo groups switched in a blinded manner to fingolimod 0.5 mg/day or continued on placebo after amendment in Nov. 2009. Patients were randomized to receive either fingolimod 0.5 mg/day or placebo..

Core Study (36 Months)
Participant flow — Core Study (36 Months)
MilestoneFTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlacebo to -FTY 0.5 mg
Started147336487
Safety set (saf)0336487
Full analysis set (fas)0336487
Pharmacokinetic analysis set1022490
Post protocol amendment 5 switch01210
Completed79220317
Not completed68116170
Withdrew: Lack of efficacy112364
Withdrew: Physician decision102
Withdrew: Death212
Withdrew: Lost to follow-up133
Withdrew: Administrative226
Withdrew: Abnormal test procedure result435
Withdrew: Protocol violation458
Withdrew: Abnormal lab values6195
Withdrew: Adverse event252829
Withdrew: Withdrawal by subject123246
Extension Phase
Participant flow — Extension Phase
MilestoneFTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlacebo to -FTY 0.5 mg
Started74196301
Completed000
Not completed74196301
Withdrew: Admin problems: terminated # patients69189277
Withdrew: Abnormal test procedure001
Withdrew: Abnormal lab values001
Withdrew: Lost to follow-up014
Withdrew: Withdrawal by subject453
Withdrew: Adverse event1115

Outcome measures

PrimaryKaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint

3-month sustained increase from Baseline in EDSS (at least 1 point increase from Baseline for patients with a Baseline value of 5 or less or at least 0.5 point increase from Baseline for patients with a Baseline value of 5.5 or more) or 3-month sustained increase of at least 20% from BL in the time taken to complete the timed 25-foot walk test (25' TWT); or 3-month sustained increase of at least 20% from BL in the time taken to complete the 9-HPT. The 25' TWT is a quantitative measure of lower extremity function. The EDSS is a scale assessing neurologic impairment, including a series of scores in each of 8 functional systems: Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. The score ranges from 0 (normal) to 10 (death due to MS)). The 9-hole peg test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function.

Time frame:
up to 36 months after the last patient was randomized
Reported as:
Number · Percentage of Participants
Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint
Percentage of ParticipantsFTY720 0.5 mg to 0.5 mgPlacebo
Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint77.2 (71.87 to 82.51)80.3 (73.31 to 87.25)
Statistical analysis
  • FTY720 0.5 mg to 0.5 mg vs Placebo · Regression, Cox · p = 0.544 · Cox proportional hazard: 0.95 · 95% CI 0.80 to 1.12
SecondaryKaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)

The Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in MS (Kurtzke 1983) and includes a series of scores in each of 8 functional systems and the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Fatigue is not included in the Cerebral score of the EDSS. The score ranges from 0 (normal) to 10 (death due to MS)

Time frame:
up to 36 months after the last patient was randomized
Reported as:
Number · Percentage of Participants
Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)
Percentage of ParticipantsFTY720 0.5 mg to 0.5 mgPlacebo
Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)54.3 (47.16 to 61.45)58.7 (53.30 to 64.18)
SecondaryPercent Change From Baseline in Brain Volume at Month 36

The percent change from Baseline in brain volume was analyzed using a random coefficients model. The model included: 1) fixed effects: treatment and region and 2) continuous covariates: time, number of Gd enhancing lesions at Baseline, Baseline T2 volume, and normalized brain volume at Baseline. Time as a continuous covariate allowed for the estimation of different slopes and intercepts among treatment groups.

Time frame:
Baseline to month 36
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Brain Volume at Month 36
Percent ChangeFTY720 0.5 mg to 0.5 mgPlacebo
Percent Change From Baseline in Brain Volume at Month 36-1.49 (-1.64 to -1.35)-1.53 (-1.65 to -1.41)
SecondaryKaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT.

The 9-HPT is a quantitative measure of upper extremity (arm and hand) function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis

Time frame:
up to 36 months after the last patient was randomized
Reported as:
Number · Percentge of Participants
Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT.
Percentge of ParticipantsFTY720 0.5 mg to 0.5 mgPlacebo
Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT.25.024.9
SecondaryKaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT.

The 25' TWT is a quantitative measure of lower extremity function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis

Time frame:
up to 36 months after the last patient was randomized
Reported as:
Number · Percentage of Participants
Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT.
Percentage of ParticipantsFTY720 0.5 mg to 0.5 mgPlacebo
Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT.54.856.7
SecondaryNumber of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36

Inflammatory disease, as measured by number of new or newly-enlarging T2 lesions, was assessed by Magnetic resonance Imaging (MRI) scanning of the brain and full spinal cord. N= Total number of patients included in the analysis

Time frame:
Baseline to 36 months
Reported as:
Least squares mean · T2 Lesions per year
Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36
T2 Lesions per yearFTY720 0.5 mg to 0.5 mgPlacebo
Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 360.13 (0.10 to 0.18)0.50 (0.40 to 0.61)
SecondaryNumber of Gd-enhancing Lesions at Month 36

Inflammatory disease, as measured by number of T1 Gd-enhancing lesions, was assessed by MRI scanning of the brain and full spinal cord. N= Total number of patients included in the analysis

Time frame:
Baseline to 36 months
Reported as:
Least squares mean · Gd-enhanced lesions per patient per scan
Number of Gd-enhancing Lesions at Month 36
Gd-enhanced lesions per patient per scanFTY720 0.5 mg to 0.5 mgPlacebo
Number of Gd-enhancing Lesions at Month 360.05 (0.02 to 0.09)0.21 (0.15 to 0.30)
SecondaryPercent Change in Total T2 Lesion Volume From Baseline to Month 36

Inflammatory disease as measured by percent change in total T2 lesion volume (mm3) was assessed by MRI. N= Total number of patients included in the analysis

Time frame:
Baseline to month 36
Reported as:
Mean · Percent Change
Percent Change in Total T2 Lesion Volume From Baseline to Month 36
Percent ChangeFTY720 0.5 mg to 0.5 mgPlacebo
Percent Change in Total T2 Lesion Volume From Baseline to Month 36-9.2 ± 30.558.9 ± 44.13
SecondaryChange From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score)

The quality of life scale contains 22 items. Each item will be given a score of 1 or 0. A score of 1 (or 0) indicates the presence (or absence) of the symptom or adverse quality of life. All 22 item scores will be summed to obtain a total score ranging from 0 (good) to 22 (poor), which is the PRIMUS QoL scale score

Time frame:
Baseline, 36 months
Reported as:
Mean · Score on a scale
Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score)
Score on a scaleFTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlacebo
Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score)0.2424 ± 4.184440.5921 ± 4.777040.9597 ± 4.38578
SecondaryChange From Baseline in PRIMUS-Activities

The activities subscale of PRIMUS contains 15 items and each item is given a score of 0 (able to do on own without difficulties), 1 (able to do on own with difficulties), or 2 (unable to do on own). All 15 items were summed to obtain a total score ranging from 0 (good) to 30 (poor).

Time frame:
Baseline, 36 months
Reported as:
Mean · Score on a scale
Change From Baseline in PRIMUS-Activities
Score on a scaleFTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlacebo
Change From Baseline in PRIMUS-Activities3.5504 ± 7.052412.6324 ± 6.222562.8830 ± 6.76499
SecondaryChange From Baseline in Unidimensional Fatigue Impact (U-FIS) Score

Unidimensional Fatigue Impact Scale (U-FIS), contains 22 patient-reported items that assess the impact of fatigue on cognitive, physical, and psychosocial functioning. Responses formed a single unidimensional scale measuring fatigue impact. The U-FIS was calculated and analyzed according to the U-FIS scoring manual. The U-FIS scale contains 22 items with 5 possible outcomes for each item. Two response categories (about half the time and a lot of the time) were combined into 1 category to obtain 4 possible outcomes: 0 (never), 1 (a little of the time), 2 (about half the time/a lot of the time), and 3 (all the time). The 22 condensed item scores were summed to obtain a total score ranging from 0 (no fatigue) to 66 (severe fatigue impact).

Time frame:
Baseline, 36 months
Reported as:
Mean · Score on a scale
Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score
Score on a scaleFTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlacebo
Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score1.3197 ± 12.440422.8451 ± 14.047693.1394 ± 12.20929
SecondaryChange From Baseline in European Quality of Life - 5 Dimensions (EQ-5D Score)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Baseline, 36 months
Reported as:
Mean · Score on a scale
Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D Score)
Score on a scaleFTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlacebo
Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D Score)-0.0332 ± 0.19420-0.0475 ± 0.26099-0.0539 ± 0.22383
SecondaryChange From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score)

The Multiple Sclerosis Walking Scaleis a patient reported measure of walking quality (Hobart et al 2003), consisting of 12 items asking patients to rate the impact of MS upon their walking ability. Responses were captured on a 3-point scale ranging from 1 (Not at all) to 3 (A lot) for items 1 to 3 and on a 5-point scale ranging from 1 (not limited) to 5 (extremely) for items 4 to 12. All 12 item scores were summed to obtain a total score ranging from 12 (good) to 54 (poor) which is the MSWS-12 scale score. The total score was transformed to a 0 to 100 scale score. The MSWS-12 scale score will be transformed to a 0-100 scale score before any summaries or statistical analyses are performed. The transformed score is obtained by subtracting 12 and divided by 42 and multiplying by 100 (i.e., transformed scale score = (raw scale score- 12)/42\*100).

Time frame:
Baseline, 36 months
Reported as:
Mean · Score on a scale
Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score)
Score on a scaleFTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlacebo
Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score)6.4444 ± 23.815685.5616 ± 24.590309.5899 ± 23.98316
SecondaryBlood Concentrations of Fingolimod and Fingolimod-phosphate

Concentrations of fingolimod and fingolimod-phosphate in whole blood were determined by validated liquid chromatography methods with tandem mass spectrometry. The lower limits of quantification were 0.08 ng/ml for fingolimod and 0.1 ng/ml for fingolimod-phosphate. Venous blood samples were collected for the analysis.

Time frame:
Month 3 up to 36 months
Reported as:
Mean · ng/ml
Blood Concentrations of Fingolimod and Fingolimod-phosphate
ng/mlFTY720 1.25 mg to 0.5 mgFTY720 1.25mg to 0.5 mgFTY720 0.5 mg to 0.5 mg
Month 3 Fingolimod (n=64, 179)6.04 ± 3.11NA ± NA2.58 ± 1.34
Month 12 Fingolimod (n=23, 161)6.24 ± 2.212.87 ± 1.702.55 ± 1.37
Month 18 Fingolimod (n=71,155)NA ± NA2.44 ± 1.152.59 ± 1.44
Month 24 Fingolimod (n=67, 160)NA ± NA2.41 ± 1.302.64 ± 1.50
Month 30 Fingolimod (n=62, 158)NA ± NA2.52 ± 1.282.60 ± 1.33
Month 36 Fingolimod (n=55, 118)NA ± NA2.44 ± 1.082.63 ± 1.38
End of treatment Fingolimod (n=32, 115)NA ± NA2.02 ± 1.102.57 ± 1.51
Month 3 Fingolimod-Phosphate (n=64, 179)3.20 ± 1.73NA ± NA1.40 ± 0.747
Month 12 Fingolimod-Phosphate (n=23, 161)3.21 ± 1.161.54 ± 0.8711.43 ± 0.805
Month 18 Fingolimod-Phosphate (n=71,155)NA ± NA1.34 ± 0.6301.41 ± 0.758
Month 24 Fingolimod-Phosphate (n=67, 160)NA ± NA1.35 ± 0.7651.44 ± 0.790
Month 30 Fingolimod-Phosphate (n=62, 158)NA ± NA1.32 ± 0.6761.48 ± 0.759
Month 36 Fingolimod-Phosphate (n=55, 118)NA ± NA1.32 ± 0.5911.51 ± 0.765
End of treatment Fingolimod-Phosphate (n=32, 115NA ± NA1.19 ± 0.6181.50 ± 0.900
SecondaryChange in MSFC Z-score and Subscale Scores From Baseline to Month 36

The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The overall MSFC z-score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population. Higher scores reflect better neurological function and a positive change from Baseline indicates improvement.

Time frame:
Baseline to Month 36
Reported as:
Mean · Z-scores
Change in MSFC Z-score and Subscale Scores From Baseline to Month 36
Z-scoresFTY720 0.5 mgPlacebo
Change in MSFC Z-score and Subscale Scores From Baseline to Month 36-0.189 ± 0.6980-0.212 ± 0.8468

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Core: FTY720 1.25 mg—38/147 (25.9%)132/147 (89.8%)
Core: FTY720 0.5 mg—84/336 (25%)278/336 (82.7%)
Core: Placebo—117/487 (24%)406/487 (83.4%)
Extension: FTY1.25-0.5—7/74 (9.5%)43/74 (58.1%)
Extension: FTY0.5-0.5—10/196 (5.1%)70/196 (35.7%)
Extension: Placebo-FTY0.5—37/301 (12.3%)138/301 (45.8%)
Most frequent serious events
Showing 10 of 268
Most frequent serious events
EventCore: FTY720 1.25 mgCore: FTY720 0.5 mgCore: PlaceboExtension: FTY1.25-0.5Extension: FTY0.5-0.5Extension: Placebo-FTY0.5
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/14711/3369/4871/742/1961/301
Urinary tract infectionInfections and infestations2/1478/33612/4871/740/1964/301
FallInjury, poisoning and procedural complications3/1471/3363/4870/740/1960/301
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1476/3361/4870/740/1961/301
BradycardiaCardiac disorders2/1472/3360/4870/740/1960/301
PneumoniaInfections and infestations2/1474/3362/4871/740/1961/301
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1471/3360/4871/740/1960/301
Multiple sclerosisNervous system disorders2/1473/3365/4870/740/1962/301
Uhthoff's phenomenonNervous system disorders2/1470/3360/4870/740/1960/301
Bursitis infectiveInfections and infestations0/1470/3360/4871/740/1960/301
Most frequent other events
Showing 10 of 33
Most frequent other events
EventCore: FTY720 1.25 mgCore: FTY720 0.5 mgCore: PlaceboExtension: FTY1.25-0.5Extension: FTY0.5-0.5Extension: Placebo-FTY0.5
NasopharyngitisInfections and infestations40/14778/336135/4879/7410/19623/301
FallInjury, poisoning and procedural complications31/14747/33691/4876/745/19613/301
HeadacheNervous system disorders28/14756/33677/4873/743/19613/301
HypertensionVascular disorders23/14743/33628/4872/745/19618/301
Urinary tract infectionInfections and infestations21/14747/33675/4874/7411/19625/301
Back painMusculoskeletal and connective tissue disorders16/14736/33675/4875/745/19610/301
Upper respiratory tract infectionInfections and infestations21/14737/33657/4876/746/19614/301
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)21/14716/33631/4874/743/1969/301
Gamma-glutamyltransferase increasedInvestigations19/14731/3363/4870/743/1965/301
Alanine aminotransferase increasedInvestigations17/14739/3367/4870/741/1966/301

Baseline characteristics

Age, Continuous
Age, Continuous(years)FTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlaceboTotal
Mean47.8 ± 8.4748.5 ± 8.5948.5 ± 8.3148.5 ± 8.42
Age, Customized
Age, Customized(Particpants)FTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlaceboTotal
<=3036413
31 to 40226090172
41 to 5068127194389
>5054143199396
Sex: Female, Male
Sex: Female, Male(Participants)FTY720 1.25 mg to 0.5 mgFTY720 0.5 mg to 0.5 mgPlaceboTotal
Female71163235469
Male76173252501
08

Study locations

157 sites
  • Novartis Investigative Site
    Newport Beach, California 92660, United States
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Pompano Beach, Florida 33060, United States
  • Novartis Investigative Site
    Tampa, Florida 33609, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30302, United States
  • Novartis Investigative Site
    Chicago, Illinois 60611, United States
  • Novartis Investigative Site
    Chicago, Illinois 60637, United States
  • Novartis Investigative Site
    Kansas City, Kansas 66160, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21287, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02135, United States
  • Novartis Investigative Site
    Brookline, Massachusetts 02445, United States
  • Novartis Investigative Site
    Detroit, Michigan 48201, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63110, United States
  • Novartis Investigative Site
    Teaneck, New Jersey 07666, United States
  • Novartis Investigative Site
    Buffalo, New York 14203, United States
  • Novartis Investigative Site
    New York, New York 10029, United States
  • Novartis Investigative Site
    Rochester, New York 14642, United States
  • Novartis Investigative Site
    Stony Brook, New York 11794, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28207, United States
  • Novartis Investigative Site
    Durham, North Carolina 27705, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44195, United States
  • Novartis Investigative Site
    Columbus, Ohio 43221, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15213, United States
  • Novartis Investigative Site
    Knoxville, Tennessee 37934, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37212, United States
  • Novartis Investigative Site
    Dallas, Texas 75390-9034, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Burlington, Vermont 05401, United States
  • Novartis Investigative Site
    Charlottesville, Virginia 22904, United States
  • Novartis Investigative Site
    Seattle, Washington 98122, United States
  • Novartis Investigative Site
    Madison, Wisconsin 53792, United States
  • Novartis Investigative Site
    Camperdown, New South Wales 2050, Australia
  • Novartis Investigative Site
    Liverpool, New South Wales 2170, Australia
  • Novartis Investigative Site
    Hobart, Tasmania 7000, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Charleroi, 6000, Belgium
  • Novartis Investigative Site
    Edegem, 2650, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Melsbroek, 1820, Belgium
  • Novartis Investigative Site
    Sint-Truiden, 3800, Belgium
  • Novartis Investigative Site
    Calgary, Alberta T2N 2T9, Canada
  • Novartis Investigative Site
    Edmonton, Alberta T6R 2B7, Canada
  • Novartis Investigative Site
    Burnaby, British Columbia V5G 2X6, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V6T 2B5, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 4K4, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5B 1W8, Canada
  • Novartis Investigative Site
    Gatineau, Quebec J9J 0A5, Canada
  • Novartis Investigative Site
    Greenfield Park, Quebec J4V 2J2, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2L 4M1, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3A 2B4, Canada
  • Novartis Investigative Site
    Regina, Saskatchewan S4T 1A5, Canada
  • Novartis Investigative Site
    Brno, Czech Republic 656 91, Czechia
  • Novartis Investigative Site
    Rychnov nad Kneznou, Czech Republic 516 01, Czechia
  • Novartis Investigative Site
    Olomouc, CZE 775 20, Czechia
  • Novartis Investigative Site
    Ostrava-Poruba, 708 00, Czechia
  • Novartis Investigative Site
    Plzen, 301 00, Czechia
  • Novartis Investigative Site
    Praha 2, 128 08, Czechia
  • Novartis Investigative Site
    Teplice, 415 29, Czechia
  • Novartis Investigative Site
    Aarhus, 8000 C, Denmark
  • Novartis Investigative Site
    Sønderborg, 6400, Denmark
  • Novartis Investigative Site
    Helsinki, 00930, Finland
  • Novartis Investigative Site
    Tampere, 33100, Finland
  • Novartis Investigative Site
    Turku, 20520, Finland
  • Novartis Investigative Site
    Bordeaux Cedex, F-33076, France
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Marseille cedex 05, 13385, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nantes Cedex 1, 44093, France
  • Novartis Investigative Site
    Paris Cedex 13, 75651, France
  • Novartis Investigative Site
    Rennes, 35043, France
  • Novartis Investigative Site
    Strasbourg, 67091, France
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 13347, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duesseldorf, D-40225, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Hennigsdorf, 16761, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Munchen, 81377, Germany
  • Novartis Investigative Site
    Teupitz, 15755, Germany
  • Novartis Investigative Site
    Trier, 54292, Germany
  • Novartis Investigative Site
    Würzburg, 97080, Germany
  • Novartis Investigative Site
    Budapest, 1076, Hungary
  • Novartis Investigative Site
    Budapest, 1145, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Gyor, 9024, Hungary
  • Novartis Investigative Site
    Miskolc, 3526, Hungary

Showing the first 100 of 157 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Leppert D, Kropshofer H, Haring DA, Dahlke F, Patil A, Meinert R, Tomic D, Kappos L, Kuhle J. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Neurology. 2022 May 24;98(21):e2120-e2131. doi: 10.1212/WNL.0000000000200258. Epub 2022 Apr 4. PubMed 35379762 ↗
  • Koch MW, Mostert J, Repovic P, Bowen JD, Strijbis E, Uitdehaag B, Cutter G. Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. J Neurol. 2022 Mar;269(3):1663-1669. doi: 10.1007/s00415-021-10750-z. Epub 2021 Aug 15. PubMed 34392376 ↗
  • Koch MW, Mostert J, Zhang Y, Wolinsky JS, Lublin FD, Strijbis E, Cutter G. Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. Neurology. 2021 Sep 28;97(13):e1334-e1342. doi: 10.1212/WNL.0000000000012603. Epub 2021 Aug 10. PubMed 34376508 ↗
  • Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli O, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Haring DA, Wolinsky JS. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar. PubMed 29560379 ↗
  • Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Haring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Erratum In: Lancet. 2017 Jan 21;389(10066):254. doi: 10.1016/S0140-6736(17)30042-9. PubMed 26827074 ↗
  • Hartung HP, Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann Neurol. 2009 Oct;66(4):429-32. doi: 10.1002/ana.21880. No abstract available. PubMed 19847907 ↗

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2008 to primary completion in Jun 2015, 82 months.

Results were first posted in Jun 2017, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2008
First posted
Aug 11, 2008
StartActual
Jul 28, 2008
Primary completionActual
Jun 22, 2015
CompletionActual
Jun 22, 2015
Results first posted
Jun 14, 2017
Last update
Jun 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00731692
Responsible party
Sponsor
First posted
Aug 11, 2008
Start date
Jul 28, 2008
Primary completion
Jun 22, 2015
Completion
Jun 22, 2015
Results posted
Jun 14, 2017
Last update
Jun 14, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion